These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 24782851)

  • 41. Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains.
    Bego MG; Cong L; Mack K; Kirchhoff F; Cohen ÉA
    J Virol; 2016 Nov; 90(22):10236-10246. PubMed ID: 27581991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiviral Activity and Adaptive Evolution of Avian Tetherins.
    Krchlíková V; Fábryová H; Hron T; Young JM; Koslová A; Hejnar J; Strebel K; Elleder D
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32238588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The great escape: viral strategies to counter BST-2/tetherin.
    Douglas JL; Gustin JK; Viswanathan K; Mansouri M; Moses AV; Früh K
    PLoS Pathog; 2010 May; 6(5):e1000913. PubMed ID: 20485522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.
    Lopez LA; Yang SJ; Exline CM; Rengarajan S; Haworth KG; Cannon PM
    J Virol; 2012 May; 86(10):5467-80. PubMed ID: 22398279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction.
    Miyakawa K; Ryo A; Murakami T; Ohba K; Yamaoka S; Fukuda M; Guatelli J; Yamamoto N
    PLoS Pathog; 2009 Dec; 5(12):e1000700. PubMed ID: 20019814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.
    Lopez LA; Yang SJ; Hauser H; Exline CM; Haworth KG; Oldenburg J; Cannon PM
    J Virol; 2010 Jul; 84(14):7243-55. PubMed ID: 20444895
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CAML does not modulate tetherin-mediated restriction of HIV-1 particle release.
    Ali MS; Hammonds J; Ding L; Spearman P
    PLoS One; 2010 Feb; 5(2):e9005. PubMed ID: 20126395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cloning and characterization of the antiviral activity of feline Tetherin/BST-2.
    Fukuma A; Abe M; Morikawa Y; Miyazawa T; Yasuda J
    PLoS One; 2011 Mar; 6(3):e18247. PubMed ID: 21479233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Three-Dimensional Structural Characterization of HIV-1 Tethered to Human Cells.
    Strauss JD; Hammonds JE; Yi H; Ding L; Spearman P; Wright ER
    J Virol; 2016 Feb; 90(3):1507-21. PubMed ID: 26582000
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tetherin restricts direct cell-to-cell infection of HIV-1.
    Kuhl BD; Sloan RD; Donahue DA; Bar-Magen T; Liang C; Wainberg MA
    Retrovirology; 2010 Dec; 7():115. PubMed ID: 21184674
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Simian immunodeficiency virus SIVagm from African green monkeys does not antagonize endogenous levels of African green monkey tetherin/BST-2.
    Lim ES; Emerman M
    J Virol; 2009 Nov; 83(22):11673-81. PubMed ID: 19726508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates.
    Chen CY; Shingai M; Welbourn S; Martin MA; Borrego P; Taveira N; Strebel K
    J Virol; 2016 Dec; 90(24):11062-11074. PubMed ID: 27681141
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
    Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
    PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.
    Fitzpatrick K; Skasko M; Deerinck TJ; Crum J; Ellisman MH; Guatelli J
    PLoS Pathog; 2010 Mar; 6(3):e1000701. PubMed ID: 20221443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of adaptation to human tetherin in HIV-1 group O and P.
    Yang SJ; Lopez LA; Exline CM; Haworth KG; Cannon PM
    Retrovirology; 2011 Sep; 8():78. PubMed ID: 21955466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tetherin restricts productive HIV-1 cell-to-cell transmission.
    Casartelli N; Sourisseau M; Feldmann J; Guivel-Benhassine F; Mallet A; Marcelin AG; Guatelli J; Schwartz O
    PLoS Pathog; 2010 Jun; 6(6):e1000955. PubMed ID: 20585562
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants.
    McNatt MW; Zang T; Hatziioannou T; Bartlett M; Fofana IB; Johnson WE; Neil SJ; Bieniasz PD
    PLoS Pathog; 2009 Feb; 5(2):e1000300. PubMed ID: 19214216
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tetherin Inhibits Nipah Virus but Not Ebola Virus Replication in Fruit Bat Cells.
    Hoffmann M; Nehlmeier I; Brinkmann C; Krähling V; Behner L; Moldenhauer AS; Krüger N; Nehls J; Schindler M; Hoenen T; Maisner A; Becker S; Pöhlmann S
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429347
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.
    Lau D; Kwan W; Guatelli J
    J Virol; 2011 Oct; 85(19):9834-46. PubMed ID: 21813615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
    Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
    PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.